Kowa Pharmaceuticals America,Inc. Announces Publication of Phase 3 Data Supporting FDA Approval of SEGLENTIS®(celecoxib 56-mg and tramadol hydrochloride 44mg)CI-V as an Efficacious Alternative for Moderate-to-Severe Acute Pain in Appropriate P - Business Wire

Phase 3 Data Publication

MONTGOMERY, Ala.--(BUSINESS WIRE)--Kowa Pharmaceuticals America, Inc. announced the publication of Phase 3 clinical trial results inPain Practice reinforcing that SEGLENTIS® a unique co-crystal combi… [+33061 chars]

full article...